Hyperfine (HYPR) Competitors $0.79 +0.06 (+8.81%) Closing price 03:55 PM EasternExtended Trading$0.78 -0.01 (-0.76%) As of 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock HYPR vs. TLSI, SGHT, BWAY, DRTS, SKIN, PROF, BSGM, INGN, ELMD, and KRMDShould you be buying Hyperfine stock or one of its competitors? The main competitors of Hyperfine include TriSalus Life Sciences (TLSI), Sight Sciences (SGHT), Brainsway (BWAY), Alpha Tau Medical (DRTS), Beauty Health (SKIN), Profound Medical (PROF), Biosig Technologies (BSGM), Inogen (INGN), Electromed (ELMD), and KORU Medical Systems (KRMD). These companies are all part of the "medical equipment" industry. Hyperfine vs. Its Competitors TriSalus Life Sciences Sight Sciences Brainsway Alpha Tau Medical Beauty Health Profound Medical Biosig Technologies Inogen Electromed KORU Medical Systems TriSalus Life Sciences (NASDAQ:TLSI) and Hyperfine (NASDAQ:HYPR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends, media sentiment and profitability. Which has preferable earnings and valuation, TLSI or HYPR? TriSalus Life Sciences has higher revenue and earnings than Hyperfine. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTriSalus Life Sciences$29.43M6.58-$30.05M-$1.12-4.57Hyperfine$12.89M4.76-$40.72M-$0.54-1.46 Do analysts prefer TLSI or HYPR? TriSalus Life Sciences currently has a consensus target price of $10.75, suggesting a potential upside of 109.96%. Hyperfine has a consensus target price of $1.06, suggesting a potential upside of 34.35%. Given TriSalus Life Sciences' stronger consensus rating and higher probable upside, research analysts plainly believe TriSalus Life Sciences is more favorable than Hyperfine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TriSalus Life Sciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25Hyperfine 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Does the media favor TLSI or HYPR? In the previous week, Hyperfine had 1 more articles in the media than TriSalus Life Sciences. MarketBeat recorded 1 mentions for Hyperfine and 0 mentions for TriSalus Life Sciences. TriSalus Life Sciences' average media sentiment score of 0.00 equaled Hyperfine'saverage media sentiment score. Company Overall Sentiment TriSalus Life Sciences Neutral Hyperfine Neutral Do insiders and institutionals have more ownership in TLSI or HYPR? 2.6% of TriSalus Life Sciences shares are held by institutional investors. Comparatively, 15.0% of Hyperfine shares are held by institutional investors. 27.5% of TriSalus Life Sciences shares are held by company insiders. Comparatively, 31.0% of Hyperfine shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more volatility and risk, TLSI or HYPR? TriSalus Life Sciences has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500. Comparatively, Hyperfine has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500. Is TLSI or HYPR more profitable? TriSalus Life Sciences has a net margin of -84.67% compared to Hyperfine's net margin of -343.42%. TriSalus Life Sciences' return on equity of 0.00% beat Hyperfine's return on equity.Company Net Margins Return on Equity Return on Assets TriSalus Life Sciences-84.67% N/A -111.63% Hyperfine -343.42%-74.19%-62.40% SummaryTriSalus Life Sciences beats Hyperfine on 9 of the 16 factors compared between the two stocks. Get Hyperfine News Delivered to You Automatically Sign up to receive the latest news and ratings for HYPR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HYPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HYPR vs. The Competition Export to ExcelMetricHyperfineMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$56.44M$6.92B$5.54B$8.95BDividend YieldN/A1.23%5.38%4.08%P/E Ratio-1.4626.6327.3820.03Price / Sales4.7699.70422.31120.16Price / CashN/A20.9736.6357.47Price / Book1.184.748.085.67Net Income-$40.72M$173.18M$3.16B$248.47M7 Day Performance7.90%1.52%2.12%2.90%1 Month Performance6.68%0.14%4.43%5.75%1 Year Performance-23.40%28.37%35.62%21.36% Hyperfine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HYPRHyperfine1.9102 of 5 stars$0.79+8.8%$1.06+34.3%-24.9%$56.44M$12.89M-1.46190News CoverageTLSITriSalus Life Sciences2.6255 of 5 stars$5.29-5.4%$10.75+103.2%-3.2%$211.52M$29.43M-4.72106Gap DownSGHTSight Sciences0.6845 of 5 stars$4.34+6.9%$4.10-5.5%-32.5%$209.88M$79.87M-4.43210BWAYBrainsway1.4323 of 5 stars$11.49+5.3%$14.25+24.0%+116.2%$206.14M$41.02M57.45120DRTSAlpha Tau Medical2.5378 of 5 stars$2.98+2.8%$8.00+168.5%+45.4%$204.10MN/A-6.4880News CoverageSKINBeauty Health0.3714 of 5 stars$1.93+19.9%$1.42-26.6%+7.7%$202.85M$334.30M-4.711,030Trending NewsGap UpHigh Trading VolumePROFProfound Medical2.69 of 5 stars$6.01-5.4%$11.50+91.3%-29.0%$190.84M$11.86M-4.93150Negative NewsBSGMBiosig Technologies0.7196 of 5 stars$7.44+11.0%$10.00+34.4%+2,656.4%$182.87M$40K0.0050High Trading VolumeINGNInogen4.4186 of 5 stars$6.67+0.5%$11.00+64.9%-3.3%$178.53M$335.70M-5.801,030ELMDElectromed1.27 of 5 stars$21.25+3.5%$38.00+78.8%+45.1%$178.20M$61.44M28.33160News CoverageKRMDKORU Medical Systems2.2591 of 5 stars$3.43+1.5%$4.50+31.2%+60.4%$155.96M$33.65M-31.1880High Trading Volume Related Companies and Tools Related Companies TriSalus Life Sciences Alternatives Sight Sciences Alternatives Brainsway Alternatives Alpha Tau Medical Alternatives Beauty Health Alternatives Profound Medical Alternatives Biosig Technologies Alternatives Inogen Alternatives Electromed Alternatives KORU Medical Systems Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HYPR) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hyperfine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hyperfine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HYPR Stock Alerts